Synuclein, alpha (SNCA) (Middle Region) Peptide
SNCA
Reactivity: Human
Host: Synthetic
BP, WB
-
- Target See all SNCA products
- SNCA (Synuclein, alpha (SNCA))
- Protein Region
- Middle Region
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-SNCA antibody (Catalog #: ARP42350_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- SNCA (Synuclein, alpha (SNCA))
- Synonyms
- snca Peptide, MGC64356 Peptide, LOC619283 Peptide, NACP Peptide, alphaSYN Peptide, PARK1 Peptide, PARK4 Peptide, PD1 Peptide, synuclein alpha L homeolog Peptide, alpha-synuclein Peptide, synuclein alpha Peptide, synuclein, alpha Peptide, snca.L Peptide, LOC619283 Peptide, SNCA Peptide, Snca Peptide
- Background
-
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease.Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced transcripts of SNCA have been identified. Additional splicing may be present but the full-length nature of these variants has not been determined.
Alias Symbols: MGC110988, NACP, PARK1, PARK4, PD1
Protein Interaction Partner: LAMP2,SNCAIP,ADRBK1,APP,BAD,BCL2L1,CALM1,COL25A1,COX3,CSNK1D,CSNK2A1,CSNK2A2,CYCS,ELK1,FGR,FYN,GRK5,GRK6,KLK6,LYN,MAP1B,MAPK1,MAPK8IP1,MAPT,PARK2,PLD1,PRKCE,PTK2B,SLC6A3,SNCAIP,SNCB,SQSTM1,SYK,TH,TOR1A,TUBA1A,UBB,YWHAB,YWHAE,YWHAH,ABZ2,ADRBK1,AIM46,ALB1,APE2,APP,ARL3,ARO1,ATG15,BAD,BAX,CALM1,CDC5,CKI1,COG6,CRH1,DPP1,EMC4,FUN26,FYN,GIP2,GLO4,GRK1,GRK5,GRK6,GTO1,GTT1,HBS1,HRD1,HSP30,INO4,MAD1,MAL31,MAP1B,MAPK1,MAPK3,MAPK8,MAPT,MEI4,MET17,MET32,MSB3,MTC2,MTC3,NAT3,NBP2,NIT2,NPP1,NUP53,OPI3,PARK2,PCA1,PDE2,PEX2,PHO13,PLD1,POX1,PSY3,PTK2,RNY1,RPL41A,SEC14,SEPT2,SEPT4,SLC6A3,SLC6A3,SNCAIP,SNCB,SOD2,SPF1,STF1,STP2,SUV3,SWR1,THI7,THR1,TLG2,TNA1,TOR1A,TSL1,UBC,UBC8,UBP3,VPS24,VPS28,VPS52,VPS60,WAR1,YAT1,YBR284W,YCK3,YCL042W,YCR050C,YCR051W,YDL118W,YFR035C,YGL262W,YGR130C,YGR201C,YJL118W,YKL100C,YKR023W,YPK9
Protein Size: 112 - Molecular Weight
- 11 kDa
- Gene ID
- 6622
- NCBI Accession
- NM_007308, NP_009292
-
You are here:
